Loading…
Context Therapeutics Inc. is projected to decline to $0.5654 by 2027, a -13% move from its current price of $0.6529. CNTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.611 | $0.6527 | $0.6973 | -0.03% |
| Jul 14 | $0.5944 | $0.6526 | $0.7164 | -0.05% |
| Jul 15 | $0.5819 | $0.6524 | $0.7315 | -0.08% |
| Jul 16 | $0.5715 | $0.6522 | $0.7443 | -0.10% |
| Jul 17 | $0.5625 | $0.6521 | $0.7558 | -0.13% |
| Jul 18 | $0.5545 | $0.6519 | $0.7664 | -0.15% |
| Jul 19 | $0.5472 | $0.6517 | $0.7761 | -0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.5472 | $0.6517 | $0.7761 | -0.18% |
| Week 2 | $0.5081 | $0.6505 | $0.8329 | -0.36% |
| Week 3 | $0.4798 | $0.6494 | $0.8789 | -0.54% |
| Week 4 | $0.457 | $0.6482 | $0.9193 | -0.72% |
| Week 5 | $0.4378 | $0.647 | $0.9563 | -0.90% |
| Week 6 | $0.421 | $0.6459 | $0.9909 | -1.08% |
| Week 7 | $0.4061 | $0.6447 | $1.02 | -1.26% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Context Therapeutics Inc. is a healthcare company focused on developing products for solid tumors. Its product candidate includes CTIM-76, a CLDN6 x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Context Therapeutics operates in the healthcare sector and focuses on clinical-stage biopharmaceutical development aimed at treating solid tumors. The description highlights CTIM-76 as a key program and the strategic collaboration with Integral Molecular to advance CLDN6-targeted cancer therapy, reflecting the company’s research and development emphasis and corporate positioning within oncology.
CNTX trades at $0.6529, with a market cap of $59.99M, and is ranked 4446.
The asset operates in the Healthcare sector and shows a defined near-term price path reflected in the year-by-year forecast.
Forecasts indicate a continued, though varied, price trajectory from 2026 through 2050, with the 2030 average at $0.838 and the 2050 average at $2.03, suggesting meaningful upside potential in the longer term. The 2050 maximum is $4.66, underscoring substantial upside in the bull scenario. For context, the 2026 average aligns with the current price at $0.6529, with longer-horizon max values reaching $1.45 (2030), $2.19 (2040), and $4.66 (2050).
A major floor 15.1% below — a decisive break under it would weaken the trend.
The nearest floor, 15.1% below — buyers have tended to step in here.
The nearest ceiling, 336.5% above — a clean break opens room to run.
A major ceiling 458.8% above — clearing it would confirm fresh momentum.
Key CNTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CNTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.6364 | Buy | $0.6302 | Buy |
| MA 10 | $0.6155 | Buy | $0.6547 | Sell |
| MA 20 | $0.6972 | Sell | $0.8516 | Sell |
| MA 50 | $1.66 | Sell | $1.41 | Sell |
| MA 100 | $2.14 | Sell | $1.72 | Sell |
| MA 200 | $1.77 | Sell | $1.71 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 31.14 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -20.77 | Neutral |
| Williams %R (14) | -32.19 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | 0.15 | Buy |
| Bollinger %B (20,2) | 0.45 | Neutral |
| Stochastic %K (14) | 67.81 | Neutral |
| TRIX (15) | -3.82 | Sell |
| Awesome (5,34) | -0.72 | Sell |
| Ultimate (7,14,28) | 53.26 | Neutral |
| Momentum (10) | 0.09 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 0.63 | Buy |
| ADX (14) | 45.72 | Sell |
| ATR (14) | 0.07 | Info |
Near-term sentiment is NEUTRAL. RSI14 is 30, and the stock trades below the SMA50 of $1.66 and the SMA200 of $1.77, signaling a softer near-term tone.
In the 30-day range, CNTX has moved between a low of $0.4225 and a high of $1.01. Key near-term levels include support at $0.554 and resistance at $2.85, outlining an upside gap relative to the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.554 | $0.6529 | $0.7332 | 0% | Neutral | |
| $0.4102 | $0.5654 | $0.8425 | -13% | Neutral | |
| $0.3369 | $0.4935 | $0.7836 | -24% | Bearish | |
| $0.4383 | $0.6763 | $1.13 | +4% | Neutral | |
| $0.5179 | $0.8377 | $1.45 | +28% | Bullish | |
| $0.4427 | $0.7483 | $1.34 | +15% | Neutral | |
| $0.4552 | $0.8027 | $1.49 | +23% | Bullish | |
| $0.4076 | $0.7484 | $1.42 | +15% | Neutral | |
| $0.3359 | $0.6417 | $1.25 | -2% | Neutral | |
| $0.4219 | $0.8377 | $1.67 | +28% | Bullish | |
| $0.449 | $0.9978 | $2.19 | +53% | Bullish | |
| $0.911 | $2.02 | $4.66 | +210% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.554 | $0.6529 | $0.7804 | +0.00% |
| August 2026 | $0.5091 | $0.6166 | $0.7778 | -5.55% |
| September 2026 | $0.5191 | $0.6377 | $0.8213 | +3.41% |
| October 2026 | $0.5078 | $0.6315 | $0.8275 | -0.98% |
| November 2026 | $0.4555 | $0.5724 | $0.7609 | -9.36% |
| December 2026 | $0.429 | $0.5443 | $0.7332 | -4.91% |
Click any year to see its month-by-month CNTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CNTX could reach as high as $0.7332, with a base case around $0.6529 and support toward $0.554 — roughly 0% from $0.6529. Price action looks broadly range-bound.
Expect CNTX to range from $0.4102 to $0.8425 through 2027. The $0.5654 average target implies a -13% move from current prices. That is -13% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The CNTX price prediction for 2028 points to an average of $0.4935 (low $0.3369, high $0.7836) — a potential decline of -24% on today's $0.6529. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2029, CNTX is projected to trade between $0.4383 and $1.13, averaging $0.6763 — a potential gain of +4% from today's $0.6529. That is up +37% on the projected 2028 average. A consolidation phase looks the most probable path here.
Context Therapeutics Inc.'s 2030 outlook centres on $0.8377, within a $0.5179 to $1.45 range. That is up +24% on the projected 2029 average. That marks a +28% change versus current levels. Momentum favours further upside here.
By 2031, CNTX could reach as high as $1.34, with a base case around $0.7483 and support toward $0.4427 — roughly +15% from $0.6529. A consolidation phase looks the most probable path here.
Expect CNTX to range from $0.4552 to $1.49 through 2032. The $0.8027 average target implies a +23% move from current prices. That is up +7% on the projected 2031 average. Momentum favours further upside here.
The CNTX price prediction for 2033 points to an average of $0.7484 (low $0.4076, high $1.42) — a potential gain of +15% on today's $0.6529. A consolidation phase looks the most probable path here.
In 2034, CNTX is projected to trade between $0.3359 and $1.25, averaging $0.6417 — a potential decline of -2% from today's $0.6529. That is -14% versus the projected 2033 average. Price action looks broadly range-bound.
Context Therapeutics Inc.'s 2035 outlook centres on $0.8377, within a $0.4219 to $1.67 range. That is up +31% on the projected 2034 average. That marks a +28% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, CNTX could reach as high as $2.19, with a base case around $0.9978 and support toward $0.449 — roughly +53% from $0.6529. Momentum favours further upside here.
Expect CNTX to range from $0.911 to $4.66 through 2050. The $2.02 average target implies a +210% move from current prices. That is up +103% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CNTX today (≈ 1,531.628121 CNTX) could be worth
$3,100.86
+$2,100.86 (+210%) by 2050 · US Dollar
Based on the average projected CNTX price of $2.02 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CNTXwould be worth at today's price.
$1,000 invested in CNTX on Jul 10, 2025 (≈ 1,492.537276 CNTX) would be worth
$974.48
-$25.52 (-2.6%) today · 0.97× · US Dollar
Based on a CNTX entry price of $0.67 vs. today's $0.6529.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.654 | $998.32 | -0.2% |
| 1 month ago | $1.45 | $450.28 | -55.0% |
| 3 months ago | $2.49 | $262.21 | -73.8% |
| 6 months ago | $1.49 | $438.19 | -56.2% |
| 1 year ago | $0.67 | $974.48 | -2.6% |
| All time (4.7y) ago | $5.1 | $128.02 | -87.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CNTX forecast.
Our base-case forecast reaches $1.30 around 2050.
Implied market cap at $1.30: $119.44M
Looking out across the multi-year forecast, CNTX shows a bullish tilt in the later years. The 2030 forecast lists an average of $0.838 with a min of $0.518 and a max of $1.45, and a ROI of 28.3% with bullish sentiment.
By 2040, the forecast envisions an average of $0.9963 and a max of $2.19, with a ROI of 52.6% and a bullish sentiment, indicating a stronger longer-horizon profile.
In 2050, the forecast projects an average of $2.03 and a max of $4.66, with a ROI of 210.3% and bullish sentiment, representing the highest long-run upside in the series. There are earlier years showing bearish turns, such as 2027 with an average of $0.5658 and ROI -13.3%, and 2028 with an average of $0.4929 and ROI -24.5%, illustrating potential near-to-mid-term volatility. These figures are estimates, not guarantees, and reflect a range of possible outcomes over time.
Tap a question to reveal the answer.
2030 avg $0.838, min $0.518, max $1.45, ROI 28.3%, sentiment Bullish.
The forecast shows bullish sentiment for 2030, 2040 and 2050 with higher averages and ROI (2030 avg $0.838, ROI 28.3%; 2040 avg $0.9963, ROI 52.6%; 2050 avg $2.03, ROI 210.3%). However, 2027 and 2028 are shown as Bearish years with negative ROI (-13.3% and -24.5%), indicating potential near-term volatility.
Yes, the 2050 max forecast is $4.66, with 2050 average $2.03 and ROI 210.3%, and the later-year sentiment is Bullish.
Current price is $0.6529 and market cap is $59.99M. The rank is 4446.
Near-term sentiment is NEUTRAL; RSI14 is 30; SMA50 is $1.66; SMA200 is $1.77; support is $0.554; resistance is $2.85. The 30-day range is $0.4225 to $1.01.
Context Therapeutics Inc. Community Discussion
0Share your Context Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.